Immunotherapy biotech unstealths with $13M; Anti-infection candidate for CF passes safety trial
Shennon Biotechnologies has raised $13 million in seed funding for a single cell platform to create more effective immunotherapies. The company says the platform can …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.